Higher Serum Sex Hormone-Binding Globulin Levels Are Associated With Incident Cardiovascular Disease in Men.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 11 06 2019
accepted: 01 08 2019
pubmed: 8 8 2019
medline: 5 6 2020
entrez: 8 8 2019
Statut: ppublish

Résumé

Sex hormone-binding globulin (SHBG) levels are associated with cardiovascular disease (CVD) risk factors. However, prospective data on the association between SHBG levels and CVD events are sparse, with conflicting results. To examine associations between serum SHBG, total testosterone (TT), and incident CVD and CVD-related mortality in middle-aged to elderly men. Data on 2563 community-dwelling men (35 to 80 years) were obtained from participants in the Men Androgen Inflammation Lifestyle Environment and Stress cohort. The analytic sample included 1492 men without baseline (2002 to 2007) CVD and with fasted morning serum SHBG and TT available at both baseline and follow-up (2007 to 2010) and without medications affecting TT or SHBG. Associations of baseline SHBG and TT, with incident CVD and CVD mortality, were analyzed using logistic regression for incident CVD and Cox proportional hazard regression for CVD mortality, adjusting for established CVD risk factors. In multivariable models, elevated baseline SHBG and lower baseline TT were independently associated with incident CVD (SHBG: OR, 1.54; 95% CI, 1.15 to 2.06 per SD increase in SHBG, P = 0.003; TT: OR, 0.71; 95% CI, 0.52 to 0.97 per SD decrease in TT; P = 0.03). A decrease in TT between time points was associated with incident CVD (OR, 0.72; 95% CI, 0.56 to 0.92; P = 0.01). Neither SHBG nor TT was significantly associated with all-age CVD mortality [hazard ratio (HR), 0.69; 95% CI, 0.29 to 1.63; P = 0.40; and HR, 0.60; 95% CI, 0.28 to 1.26; P = 0.18, respectively]. Among all men and men >65 years, elevated SHBG and lower TT were independently associated with both a greater risk of CVD and an increased CVD mortality risk.

Identifiants

pubmed: 31390027
pii: 5544495
doi: 10.1210/jc.2019-01317
doi:

Substances chimiques

Biomarkers 0
Sex Hormone-Binding Globulin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6301-6315

Informations de copyright

Copyright © 2019 Endocrine Society.

Auteurs

Prabin Gyawali (P)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Sean A Martin (SA)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Leonie K Heilbronn (LK)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Andrew D Vincent (AD)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Alicia J Jenkins (AJ)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

Andrzej S Januszewski (AS)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

Robert J T Adams (RJT)

Adelaide Institute for Sleep Health, Flinders University, Adelaide, South Australia, Australia.

Peter D O'Loughlin (PD)

Chemical Pathology, SA Pathology, Adelaide, South Australia, Australia.

Gary A Wittert (GA)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH